Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Helle
Helle Bielefeldt-Ohmann, Queensland AU
| Patent application number | Description | Published |
|---|---|---|
| 20100112004 | HYPOXIA INDUCIBLE FACTOR INDUCER AND METHODS FOR USING THE SAME - The present invention provides vaccine compositions and methods for using the same. Generally, the vaccine is used to prevent infection of a microorganism that produces an HIF inducing compound. Accordingly, vaccines of the invention comprise at least a portion of an HIF inducing compound that is produced by the microorganism. | 05-06-2010 |
Helle Demuth, Rungsted Kyst DK
| Patent application number | Description | Published |
|---|---|---|
| 20110306548 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation. | 12-15-2011 |
Helle Funch Nielsen, Hoersholm DK
| Patent application number | Description | Published |
|---|---|---|
| 20110214671 | INHALER ASSEMBLY - The present invention provides an inhaler assembly for providing medications in aerosol form to animals, especially equines. The inhaler assembly comprises a holder adapted to retain at least two diffusion canisters containing either substantially the same or different drug formulations. The canister holder has an outlet in communication with the inlet of a spacer. The spacer, in turn, has an outlet in communication with a mask such that, in use, medication from at least one of the canisters can be dispensed into the spacer for inhalation in aerosol form via the mask. | 09-08-2011 |
Helle KayerØd, Nærum DK
| Patent application number | Description | Published |
|---|---|---|
| 20100306893 | PROTECTIVE FACE MASK - A protective face mask includes an eye-protecting shield made essentially from a plastics material. The eye-protecting shield is dimensioned to cover at least the eye portions of a human wearer. The eye-protecting shield has a perimeter defining a first surface facing the wearer's face, and a second surface facing away from the wearer's face. An adhesive forms an adhesive strip attached to the first surface of the eye-protecting shield for providing a substantially watertight and releasable sealing engagement between at least a portion of the perimeter forming an upper edge of the face mask and at least a portion of the skin of the wearer's face. | 12-09-2010 |
Helle Kuura, Tartu EE
| Patent application number | Description | Published |
|---|---|---|
| 20090117094 | Method Of Making The Porous Carbon Material And Porous Carbon Materials Produced By The Method - A method for making the microporous carbon with modified pore size distribution and advanced sorption behaviour. The carbon is derived from metal or metalloid carbides. The method employs the use of oxidant in reaction medium that during the carbide conversion into carbon widens small micropores, which otherwise would be hardly accessed by sorbing molecules or ions in practical applications. The microporous carbon obtained is free of impurities and possesses extremely narrow pore size distribution. | 05-07-2009 |
Helle Naver, Allerod DK
| Patent application number | Description | Published |
|---|---|---|
| 20090069216 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 03-12-2009 |
| 20110009314 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 01-13-2011 |
Helle Naver, Bagsvaerd DK
| Patent application number | Description | Published |
|---|---|---|
| 20120135920 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 05-31-2012 |
Helle Sadam, Tallinn EE
| Patent application number | Description | Published |
|---|---|---|
| 20080206770 | SCREENING METHODS USED TO IDENTIFY COMPOUNDS THAT MODULATE SKIN STROMAL CELLS (FIBROBLASTS) ABILITY TO MODIFY FUNCTION OF EXTRACELLULAR MATRIX - The cellular response to cosmetic products has been characterized on the molecular level through the use of gene and protein expression technologies. Nucleic acid and protein molecules, the expression of which are induced or repressed in response to exposure to cosmetics, are identified according to a temporal pattern of altered expression post exposure. Methods are disclosed that utilized these cosmetics-regulated molecules as markers for effectiveness of cosmetics. Other screening methods of the invention are designed for the identification of compounds that modulate the response of a cell to exposure to cosmetics. The invention also provides compositions useful for drug screening or pharmaceutical purposes. | 08-28-2008 |
Helle Wöldike, Lynge DK
| Patent application number | Description | Published |
|---|---|---|
| 20090035821 | Expression of Proteins in E.Coli - Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX | 02-05-2009 |
| 20090253864 | IL-21 Derivatives and Variants - The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules. | 10-08-2009 |
| 20100041153 | Expression of Proteins in E. Coli - Plasmid comprising a DNA tag encoding a peptide tag of the sequence MX1(X 2X 3) n X 1 represents K or R; X 2 represents M, S or T; X 3 represents K or R; n represents an integer of 1 or larger; and wherein said DNA is operably-linked to a promoter sequence are provided. | 02-18-2010 |
| 20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |
Helle Wöldike, Lynge DK
| Patent application number | Description | Published |
|---|---|---|
| 20100216715 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use - The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability. | 08-26-2010 |
| 20120035099 | FGF21 ANALOGUES AND DERIVATIVES - Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process. | 02-09-2012 |